Clinical Trials in Houston Texas

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression
NCT04011592
Condition: Post Partum Depression
Interventions: Drug: Ketamine 0.5 mg/kg; Drug: Ketamine 0.2 mg/kg
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Quit4Health Intervention in Supporting Smoking Cessation and Preventing Smoking Initiation in Young Adults
NCT04009590
Conditions: Cigarette Smoking; Current Smoker
Interventions: Other: Educational Intervention; Other: Questionnaire Administration; Behavioral: Smoking Cessation Intervention
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
NCT03961360
Conditions: Pre-Eclampsia; Hypertension in Pregnancy; Obesity
Interventions: Drug: Aspirin 81 mg; Drug: Aspirin 162 mg
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Brief Personalized Feedback Intervention for Hazardous Drinking in an HIV Clinic
NCT03935945
Condition: Alcohol Consumption
Intervention: Behavioral: Personalized Feedback Intervention
Sponsors: University of Houston; Baylor College of Medicine
Recruiting
The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width
NCT03926975
Condition: Ocular Hypertension
Interventions: Device: Scleral Lens; Other: No lens
Sponsor: University of Houston
Recruiting
Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
NCT03860753
Condition: Alcohol Use Disorder
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care
NCT03857659
Conditions: Fetal Growth Abnormality; Amniotic Fluid; Disorder
Interventions: Diagnostic Test: Point-of-care ultrasound (POC-US); Diagnostic Test: Routine antenatal care; Diagnostic Test: Formal ultrasound
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Electrophysiological Biomarkers of AV-101
NCT03583554
Condition: Healthy
Interventions: Drug: AV-101 720 mg; Drug: Placebo; Drug: AV-101 1440 mg
Sponsors: Marijn Lijffijt, PhD; Michael Debakey Veterans Affairs Medical Center; VistaGen Therapeutics, Inc.
Recruiting
Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
NCT03539887
Conditions: Suicidal Ideation; Depression; Alcohol Abuse
Interventions: Drug: Intranasal ketamine; Drug: Placebo
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Project PRIDE (Promoting Resilience In Discriminatory Environments)
NCT03528135
Conditions: Human Immunodeficiency Virus; Sexually Transmitted Infections; Anxiety; Depression; Substance Use Disorders
Intervention: Behavioral: Project PRIDE
Sponsors: University of Houston; National Institute on Drug Abuse (NIDA)
Recruiting
Neurofeedback for PTSD
NCT03482466
Condition: Post-traumatic Stress Disorder
Intervention: Behavioral: Neurofeedback
Sponsors: VA Office of Research and Development; Baylor College of Medicine
Recruiting
Zonisamide Outpatient Study
NCT03376139
Conditions: Post Traumatic Stress Disorder; Alcohol Use Disorder
Interventions: Drug: Zonisamide; Drug: Placebo Comparator
Sponsors: Pharmacotherapies for Alcohol and Substance Abuse Consortium; Congressionally Directed Medical Research Programs; Michael Debakey Veterans Affairs Medical Center; Baylor College of Medicine
Recruiting
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
NCT02896712
Condition: Cocaine-Related Disorders
Interventions: Behavioral: Acceptance and Commitment Therapy (ACT); Behavioral: Drug Counseling (DC); Behavioral: Contingency Management (CM); Drug: Placebo; Drug: Modafinil
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia
NCT00881660
Condition: Congenital Diaphragmatic Hernia
Intervention: Device: Goldballoon Detachable Balloon and delivery microcatheter
Sponsors: Michael Belfort; Baylor College of Medicine; Texas Children's Hospital
Recruiting
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04054167
Conditions: Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
Intervention: Drug: Low Dose Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy
NCT04054154
Condition: Solid Neoplasm
Interventions: Device: Shear Wave Elastography; Procedure: Tumor Interstitial Fluid Pressure Measurement
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Financial Distress in Advanced Cancer Patients
NCT04053517
Conditions: Advanced Malignant Neoplasm; Locally Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm; Refractory Malignant Neoplasm
Interventions: Other: Medical Chart Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
NCT04030455
Conditions: Laryngeal Squamous Cell Carcinoma; Stage II Laryngeal Cancer AJCC v8; Stage III Laryngeal Cancer AJCC v8
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Docetaxel; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors
NCT04027400
Conditions: Cognitive Impairment; Breast Cancer
Intervention: Behavioral: computer-assisted rehabilitation
Sponsor: Texas Woman's University
Recruiting
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
NCT04022772
Condition: Breast Carcinoma
Interventions: Other: Best Practice; Other: Medical Chart Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Supportive Care
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Genentech, Inc.
Recruiting
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
NCT04022746
Conditions: Advanced Adult Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8
Interventions: Procedure: Magnetic Resonance Elastography; Procedure: Magnetic Resonance Imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Caring for Caregivers With Mind-body Exercise
NCT04019301
Conditions: Caregiver Distress; Physical Function; Quality of Life
Interventions: Other: Baduanjin Qigong, Community-based; Other: Baduanjin Qigong, Internet-based
Sponsors: Texas Woman's University; Brigham and Women's Hospital
Recruiting
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT04017650
Conditions: BRAF NP_004324.2:p.V600E; Metastatic Colon Adenocarcinoma; Metastatic Microsatellite Stable Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Progressive Disease; Recurrent Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectable Rectal Adenocarcinoma
Interventions: Biological: Cetuximab; Drug: Encorafenib; Biological: Nivolumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
NCT04017546
Conditions: AML; MDS
Interventions: Drug: CYC065; Drug: Venetoclax
Sponsors: Cyclacel Pharmaceuticals, Inc.; M.D. Anderson Cancer Center
Recruiting
Web-Based Program in Helping Patients With Head and Neck Cancer Adhere to Swallowing Exercises and Coping Strategies
NCT04003051
Conditions: Glottis Carcinoma; Positive Lymph Node; Stage II Laryngeal Cancer AJCC v8; Stage II Pharyngeal Cancer; Stage III Laryngeal Cancer AJCC v8; Stage III Pharyngeal Cancer; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Pharyngeal Cancer; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Pharyngeal Cancer
Interventions: Other: Internet-Based Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT04003038
Conditions: Body Mass Index Greater Than or Equal to 30; Malignant Breast Neoplasm; Mammoplasty Patient; Obesity
Interventions: Procedure: Negative Pressure Wound Therapy; Procedure: Wound Care Management
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
NCT03990623
Condition: Liver and Intrahepatic Bile Duct Carcinoma
Interventions: Radiation: Computed Tomography Perfusion Imaging; Procedure: Liver Biopsy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT03990610
Conditions: Breast Carcinoma; Mammoplasty Patient
Interventions: Procedure: Mammoplasty; Procedure: Vascularized Lymph Node Transfer
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT03990571
Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Survey of Cancer Patients' Perceptions of Difficulties Encountered When Filling Opioid Prescriptions
NCT03989128
Conditions: Malignant Neoplasm; Pain
Interventions: Other: Medical Chart Review; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT03987386
Conditions: Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8
Interventions: Radiation: Hypofractionated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality
NCT03980535
Conditions: Health Status Unknown; Healthy Subject
Interventions: Procedure: Magnetic Resonance Imaging; Procedure: Magnetic Resonance Spectroscopic Imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
SuperNO2VA™ and General Anesthesia Postoperative Care
NCT03969615
Conditions: Hypoxemia; Acute Respiratory Failure
Interventions: Device: SuperNO2VA nasal positive airway pressure devic; Device: Supplemental oxygen
Sponsors: Vyaire Medical; M.D. Anderson Cancer Center
Recruiting
Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients
NCT03968328
Conditions: Febrile Neutropenia; Fever
Interventions: Other: Interview; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
NCT03965481
Conditions: Malignant Ovarian Neoplasm; Ovarian Carcinoma
Interventions: Radiation: Dynamic Enhanced CT; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Resting-State Functional MRI in Glioma Patients Before and After Surgery
NCT03964909
Conditions: Brain Mass; Glioma
Interventions: Procedure: Functional Magnetic Resonance Imaging; Procedure: Magnetic Resonance Imaging; Procedure: Resting State Functional Connectivity Magnetic Resonance Imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT03960463
Conditions: Surgical Wound; Diabetes; Amputation Wound; Incision Wound; Peripheral Arterial Disease; Breast Cancer; Diabetic Foot
Intervention: Device: Transcu O2®
Sponsors: Baylor College of Medicine; Electrochemical Oxygen Concepts, Inc.
Recruiting
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
NCT03953131
Condition: Meningioma
Interventions: Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Dietary Intervention in Patients With a History of Melanoma
NCT03950635
Conditions: Melanoma; No Evidence of Disease
Interventions: Dietary Supplement: Dietary Intervention; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
NCT03950609
Conditions: Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor
Interventions: Drug: Everolimus; Drug: Lenvatinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-III Non-small Cell Lung Cancer Undergoing Radiotherapy and Their Caregivers
NCT03948100
Conditions: Caregiver; Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Other: Educational Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Yoga
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT03946878
Conditions: Blastoid Variant Mantle Cell Lymphoma; CCND1 Protein Overexpression; CD20 Positive; CD5 Positive; FCER2 Negative; Pleomorphic Variant Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; t(11;14)(q13;q32)
Interventions: Drug: Acalabrutinib; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Postmenopausal Pessary Users: Estrogen Versus Trimosan
NCT03943823
Conditions: Vaginosis; Vaginosis, Bacterial; Vaginal Discharge
Interventions: Drug: Estrogen vaginal cream; Drug: Trimo-San vaginal gel
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT03943173
Conditions: BRCA-Mutated Ovarian Carcinoma; BRCA1 Gene Mutation; BRCA2 Gene Mutation; High Grade Fallopian Tube Serous Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IIIA Fallopian Tube Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Primary Peritoneal Cancer AJCC v8; Stage IIIA1 Fallopian Tube Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Fallopian Tube Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Fallopian Tube Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Primary Peritoneal Cancer AJCC v8; Stage IIIC Fallopian Tube Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions: Drug: Chemotherapy; Drug: Olaparib; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT03941756
Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Inflammatory Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Indocyanine Green; Procedure: Lymphangiography; Procedure: Lymphovenous Bypass
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
NCT03927885
Conditions: Advanced Malignant Solid Neoplasm; Cancer Fatigue; Metastatic Malignant Solid Neoplasm; Pain; Recurrent Malignant Solid Neoplasm
Interventions: Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Waiting List
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery
NCT03926507
Condition: Glioblastoma
Interventions: Procedure: Computed Tomography; Other: Fluciclovine F18; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Personalized Feedback for Distress Intolerant Smokers
NCT03918031
Conditions: Anxiety Disorders; Depression; Psychological Distress; Tobacco Dependence; Smoking, Tobacco; Smoking, Cigarette
Interventions: Behavioral: PFI for Smoking & Distress Tolerance; Behavioral: PFI for Smoking Only
Sponsors: University of Houston; National Institute on Drug Abuse (NIDA)
Recruiting
Computer-Delivered PFI for Anxiety Sensitivity/Alcohol Intervention for Hazardous Drinkers With Elevated Anxiety Sensitivity
NCT03917875
Conditions: Alcohol Drinking; Anxiety; Coping Behavior
Intervention: Behavioral: Personalized feedback intervention
Sponsor: University of Houston
Recruiting
Peer-led Group Intervention for Coping With Disaster
NCT03907995
Conditions: Anxiety Disorder; PTSD; Depressive Symptoms; Anger; Depressive Disorder
Intervention: Behavioral: Cognitive Behavioral Therapy
Sponsors: Baylor College of Medicine; American National Red Cross
Recruiting
Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
NCT03896568
Conditions: IDH1 wt Allele; Recurrent Anaplastic Astrocytoma; Recurrent Glioblastoma; Recurrent Gliosarcoma; Recurrent Malignant Glioma
Interventions: Biological: Oncolytic Adenovirus Ad5-DNX-2401; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03896269
Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells; Blasts More Than 5 Percent of Bone Marrow Nucleated Cells; High Risk Chronic Myelomonocytic Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory High Risk Myelodysplastic Syndrome
Intervention: Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
NCT03894540
Condition: Solid Tumor
Interventions: Drug: IPN60090; Drug: pembrolizumab; Drug: paclitaxel
Sponsor: Ipsen
Recruiting
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
NCT03892993
Conditions: Cancer Survivor; Caregiver; Family Member; Health Care Provider; Thyroid Gland Medullary Carcinoma
Interventions: Other: Decision Aid; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers
NCT03888651
Condition: Head and Neck Carcinoma
Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
NCT03884972
Conditions: Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Trabectedin; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
NCT03884829
Conditions: AML, Adult; Myelodysplastic Syndromes; ALL, Adult; CML, Refractory; CLL, Refractory
Intervention: Drug: CYC140
Sponsors: Cyclacel Pharmaceuticals, Inc.; M.D. Anderson Cancer Center
Recruiting
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT03873818
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Malignant Neoplasm in the Brain; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Ipilimumab; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
NCT03872388
Conditions: Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Inflammatory Breast Carcinoma; Progesterone Receptor Negative; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Drug: Atorvastatin; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
NCT03868020
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions: Procedure: Computed Tomography; Radiation: Fluciclovine F18; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03862157
Conditions: Acute Myeloid Leukemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Eosinophilic Leukemia, Not Otherwise Specified; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Dysplasia; Essential Thrombocythemia; FGFR1 Gene Rearrangement; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloid Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Overt Primary Myelofibrosis; PDGFRA Gene Rearrangement; PDGFRB Gene Rearrangement; Polycythemia Vera; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Prefibrotic/Early Primary Myelofibrosis
Interventions: Drug: Azacitidine; Drug: Pevonedistat; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
NCT03856060
Conditions: Advanced Malignant Neoplasm; Locally Advanced Malignant Neoplasm; Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm
Interventions: Other: Questionnaire Administration; Other: Video
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
NCT03854019
Conditions: Huntington Disease; Irritability
Interventions: Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg); Drug: Placebo
Sponsors: The University of Texas Health Science Center, Houston; Cures Within Reach
Recruiting
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
NCT03852511
Conditions: Metastatic Cancer; Epithelial Tumor
Intervention: Biological: NG-350A
Sponsor: PsiOxus Therapeutics Ltd
Recruiting
Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease
NCT03827564
Condition: Dry Eye Syndromes
Intervention: Device: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
Sponsor: Allergan
Recruiting
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
NCT03821792
Conditions: Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Carcinoma Metastatic in the Bone; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Interventions: Drug: Abiraterone Acetate; Drug: Apalutamide; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
AVAZZIA Electrical Stimulation
NCT03821675
Conditions: Diabetes; Diabetic Foot Ulcer; Peripheral Neuropathy; Peripheral Arterial Disease
Interventions: Device: Electrical Stimulation; Device: Electrical Stimulation - Sham
Sponsors: Baylor College of Medicine; Avazzia, Inc; Brian Lepow, DPM
Recruiting
Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
NCT03819985
Conditions: Resectable Soft Tissue Sarcoma; Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Interventions: Radiation: Hypofractionated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pain Control With Pre-operative Cryoneurolysis Following TKA
NCT03818022
Condition: Osteo Arthritis Knee
Intervention: Procedure: Cryoneurolysis (Iovera)
Sponsor: Fondren Orthopedic Group L.L.P.
Recruiting
Transdiagnostic CBT for Anxiety
NCT03810456
Condition: Anxiety Disorders
Interventions: Behavioral: Intensive Cognitive Behavior Therapy (iCBT); Behavioral: Standard Cognitive Behavior Therapy (sCBT)
Sponsor: VA Office of Research and Development
Recruiting
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
NCT03808610
Conditions: Recurrent B Acute Lymphoblastic Leukemia; Recurrent T Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory T Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Nelarabine; Drug: Pegaspargase; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Expanding the UTHealth Medical Legal Partnership to Improve Mental Health for Low-Income Individuals
NCT03805126
Condition: Health-harming Legal Needs
Interventions: Behavioral: Medical Legal Partnership; Behavioral: Usual Care
Sponsors: The University of Texas Health Science Center, Houston; Texas Medical Center Foundation; University of Houston; William Marsh Rice University
Recruiting
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
NCT03784677
Conditions: Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Ovarian Carcinoma; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Intervention: Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer
NCT03784326
Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions: Drug: Atezolizumab; Procedure: Conventional Surgery; Drug: Fluorouracil; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487
Conditions: Clinical Stage 0 Gastric Cancer AJCC v8; Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage I Gastric Cancer AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Gastric Cancer AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastric Cancer AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Gastric Adenocarcinoma; Localized Gastric Carcinoma; Localized Gastroesophageal Junction Adenocarcinoma; Pathologic Stage 0 Gastric Cancer AJCC v8; Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage I Gastric Cancer AJCC v8; Pathologic Stage IA Gastric Cancer AJCC v8; Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IB Gastric Cancer AJCC v8; Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastric Cancer AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastric Cancer AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastric Cancer AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions: Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Biological: Ipilimumab; Biological: Nivolumab; Drug: Oxaliplatin; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders
NCT03775681
Conditions: Bile Duct Disorder; Endocrine Pancreas Disorder
Interventions: Procedure: Endoscopic Retrograde Cholangiopancreatography; Other: Interview; Device: Laryngeal Mask Airway
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
NCT03773393
Condition: Bone Marrow Disease
Intervention: Biological: CK0801
Sponsor: Cellenkos, Inc.
Recruiting
Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
NCT03772834
Conditions: Fatigue; Prostate Carcinoma
Interventions: Behavioral: Exercise Intervention; Drug: Methylphenidate; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Stretching
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Diagnostic Modalities for Severe Odontogenic Infections Using Rapid, Target Enriched Multiplex PCR (TEM- PCR) by Diatherix
NCT03772769
Condition: Odontogenic Deep Space Neck Infection
Interventions: Diagnostic Test: Target Enriched Multiplex PCR (TEM- PCR); Diagnostic Test: Microbial culture
Sponsors: The University of Texas Health Science Center, Houston; Eurofins
Recruiting
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
NCT03770416
Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma; Recurrent Central Nervous System Lymphoma; Refractory Central Nervous System Lymphoma
Interventions: Drug: Ibrutinib; Biological: Nivolumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT03763162
Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Interventions: Drug: Bortezomib; Biological: Daratumumab; Drug: Dexamethasone; Drug: Ixazomib; Other: Quality-of-Life Assessment
Sponsors: M.D. Anderson Cancer Center; Takeda
Recruiting
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT03756818
Conditions: Advanced Malignant Solid Neoplasm; KRAS Gene Mutation; Ovarian Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Ovarian Carcinoma
Interventions: Drug: Paclitaxel; Other: Pharmacokinetic Study; Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
NCT03747757
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Cancer Fatigue; Lymphoma; Secondary Acute Myeloid Leukemia
Interventions: Behavioral: Cognitive Behavior Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Self Transcranial Direct Current Stimulation and Mindfulness-based Meditation for Pain in Older Adults With Knee Osteoarthritis
NCT03747640
Condition: Knee Osteoarthritis
Interventions: Device: Self Transcranial Direct Current Stimulation (tDCS); Behavioral: mindfulness-based meditation; Device: Sham Self Transcranial Direct Current Stimulation (tDCS); Behavioral: sham meditation
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
NCT03745794
Condition: Pancreatic Carcinoma
Interventions: Other: Best Practice; Drug: Quadratus Lumborum Block; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
NCT03744793
Conditions: Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation; Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation; Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Urothelial Carcinoma; MTAP Negative
Interventions: Drug: Avelumab; Drug: Pemetrexed
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
NCT03741673
Conditions: Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain
Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Stereotactic Radiosurgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
NCT03740100
Condition: HNSCC
Intervention: Drug: Bimiralisib
Sponsor: PIQUR Therapeutics AG
Recruiting
Daily Meditation Program in Women Admitted to the Antepartum Unit
NCT03737279
Conditions: Pregnancy, High Risk; Pregnancy Related
Interventions: Behavioral: Meditation; Behavioral: Routine Care
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
NCT03735875
Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation; FLT3 Gene Mutation; FLT3 Internal Tandem Duplication; Recurrent Acute Myeloid Leukemia; Refractory Acute Leukemia
Interventions: Drug: Quizartinib; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
NCT03725436
Conditions: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Recurrent Breast Carcinoma; TP53 wt Allele; Unresectable Malignant Solid Neoplasm
Interventions: Drug: MDM2/MDMX Inhibitor ALRN-6924; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site
NCT03713073
Condition: Palatal Wound
Interventions: Device: Allogenic amnion chorion membrane; Device: Collagen dressing
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT03710772
Conditions: CD20 Positive; Mantle Cell Lymphoma
Interventions: Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Doxorubicin Hydrochloride; Drug: Ibrutinib; Drug: Methotrexate; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
NCT03707938
Conditions: Advanced Lung Carcinoma; ALK Gene Rearrangement; Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Brigatinib; Procedure: Local Consolidation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
NCT03707925
Conditions: Lung Carcinoid Tumor; Lung Non-Small Cell Carcinoma; Metastatic Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Procedure: Cone-Beam Computed Tomography; Procedure: Conventional Surgery; Procedure: Laser Ablation
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer
NCT03690921
Conditions: Anal Canal Squamous Cell Carcinoma; Stage I Anal Cancer AJCC v8; Stage II Anal Cancer AJCC v8; Stage IIA Anal Cancer AJCC v8; Stage IIB Anal Cancer AJCC v8; Stage III Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Drug: Cisplatin; Drug: Fluorouracil; Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
TCR-engineered T Cells in Solid Tumors
NCT03686124
Conditions: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult; Cancer
Interventions: Biological: IMA203 Product; Device: IMADetect
Sponsors: Immatics US, Inc.; M.D. Anderson Cancer Center
Recruiting
DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis
NCT03685539
Conditions: Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain
Intervention: Procedure: Dual-Energy Computed Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
NCT03683433
Conditions: Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Chronic Myelomonocytic Leukemia; IDH2 Gene Mutation; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Drug: Azacitidine; Drug: Enasidenib Mesylate
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
NCT03680586
Condition: Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Intervention: Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Electronic Neurocognitive Tools in Screening for Mental Capability in Patients Undergoing Liver Surgery
NCT03678441
Condition: Liver and Intrahepatic Bile Duct Disorder
Interventions: Behavioral: BrainCheck Cognitive Assessment; Procedure: Cognitive Assessment
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
NCT03672539
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; Blasts More Than 10 Percent of Peripheral Blood White Cells; CD33 Positive; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Drug: Gemtuzumab Ozogamicin; Drug: Liposome-encapsulated Daunorubicin-Cytarabine; Other: Quality-of-Life Assessment
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
NCT03672292
Condition: Invasive Pulmonary Aspergillosis
Interventions: Drug: SCY-078; Drug: Voriconazole; Other: Oral Placebo Tablets
Sponsor: Scynexis, Inc.
Recruiting
Study of the Fecal Microbiome in Patients With Parkinson's Disease
NCT03671785
Condition: Parkinson Disease
Interventions: Drug: PRIM-DJ2727; Drug: Placebo oral capsule
Sponsors: The University of Texas Health Science Center, Houston; Kelsey Research Foundation
Recruiting
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT03661307
Conditions: Acute Myeloid Leukemia; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; Blasts More Than 10 Percent of Peripheral Blood White Cells; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; TP53 Gene Deletion; TP53 Gene Mutation
Interventions: Drug: Decitabine; Drug: Quizartinib; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Survey of Post-Acute Inpatient Rehabilitation Safety Concerns in Participants With Cancer
NCT03656224
Condition: Malignant Neoplasm
Intervention: Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
NCT03654547
Conditions: Advanced Solid Tumors; Triple Negative Breast Cancer
Intervention: Drug: TT-00420
Sponsor: TransThera Biosciences Co., Ltd
Recruiting
Improving Quality of Life for Veterans With Stroke and Psychological Distress
NCT03645759
Conditions: Stroke; Depression; Anxiety
Interventions: Behavioral: I'm Whole; Other: Education + usual care
Sponsor: VA Office of Research and Development
Recruiting
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
NCT03637816
Conditions: Anorexia; Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Anamorelin Hydrochloride; Other: Placebo; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
MRx0518 and Pembrolizumab Combination Study
NCT03637803
Conditions: Oncology; Solid Tumor; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma; Bladder Cancer
Interventions: Drug: MRx0518; Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Sponsors: 4D pharma plc; Merck Sharp & Dohme Corp.
Recruiting
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
NCT03634267
Conditions: Human Papillomavirus-Related Carcinoma; Human Papillomavirus-Related Cervical Carcinoma; Stage IB2 Cervical Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage II Vaginal Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA Vaginal Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIB Vaginal Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Vaginal Cancer AJCC v8; Stage IIIA Cervical Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8
Interventions: Radiation: Internal Radiation Therapy; Procedure: Magnetic Resonance Imaging
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Participants With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules
NCT03634241
Conditions: Lung Non-Small Cell Carcinoma; Pulmonary Nodule; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8
Interventions: Other: Best Practice; Biological: Pembrolizumab; Other: Quality-of-Life Assessment
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
NCT03634228
Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; TP53 wt Allele
Interventions: Drug: Cytarabine; Drug: Milademetan Tosylate
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
NCT03630991
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia
Interventions: Drug: Edetate Calcium Disodium; Dietary Supplement: Multivitamin; Drug: Succimer
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
NCT03630302
Condition: Parkinson
Intervention: Device: DBS
Sponsors: Abbott Medical Devices; Baylor College of Medicine; University of Houston
Recruiting
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
NCT03629171
Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
NCT03622775
Condition: Recurrent Plasma Cell Myeloma
Intervention: Biological: Daratumumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT03620201
Condition: Malignant Neoplasm of Breast
Interventions: Drug: M7824 - patients with Stage II or III HER2+ breast cancer; Drug: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; EMD Serono
Recruiting
Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors
NCT03612531
Conditions: Cancer Survivor; Dysphagia; Fibrosis; Head and Neck Carcinoma
Intervention: Procedure: Manual Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
NCT03607825
Condition: Subarachnoid Hemorrhage
Intervention: Device: Neurapheresis System
Sponsor: Minnetronix
Recruiting
Fluorine F 18 Fluorthanatrace PET/CT in Treating Patients With Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03604315
Conditions: Breast Carcinoma; Fallopian Tube Carcinoma; Ovarian Carcinoma; Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm
Interventions: Procedure: Computed Tomography; Radiation: Fludeoxyglucose F-18; Radiation: Fluorine F 18 Fluorthanatrace; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT03600155
Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Endometrial Adenocarcinoma; High Grade Ovarian Serous Adenocarcinoma; Platinum-Resistant Ovarian Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Progressive Disease; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Copanlisib; Drug: Niraparib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT03586609
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitidine; Drug: Cladribine; Drug: Cytarabine; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
NCT03581487
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Biological: Durvalumab; Drug: Selumetinib; Biological: Tremelimumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03579472
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Triple-Negative Breast Carcinoma; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824; Drug: Eribulin Mesylate
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
NCT03579446
Conditions: Malignant Neoplasm; Metastatic Malignant Neoplasm; Pain
Interventions: Drug: Hydrocodone; Drug: Hydromorphone; Drug: Hydromorphone Hydrochloride; Drug: Levorphanol; Drug: Morphine; Drug: Morphine Sulfate; Drug: Oxycodone; Drug: Oxymorphone; Drug: Oxymorphone Hydrochloride; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
NCT03576547
Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Lymphoblastic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; t(9;22)
Interventions: Drug: Dexamethasone; Drug: Ponatinib Hydrochloride; Biological: Rituximab; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer
NCT03575949
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Malignant Neoplasm in the Spine; Positive Lymph Node
Interventions: Procedure: Computed Tomography; Other: Fludeoxyglucose F-18; Procedure: Positron Emission Tomography
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Brain Targets in Patients With Bladder Emptying Difficulties
NCT03574610
Conditions: Neurogenic Bladder; Multiple Sclerosis; Parkinson Disease; Voiding Dysfunction
Intervention: Device: Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
Sponsors: Rose Khavari, M.D.; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
NCT03573544
Conditions: Metastatic Solid Tumors; Locally Advanced Solid Tumors
Interventions: Drug: OBI-888; Device: Globo H IHC Assay
Sponsor: OBI Pharma, Inc
Recruiting
Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery
NCT03565783
Conditions: Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Resectable Head and Neck Squamous Cell Carcinoma; Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Intervention: Biological: Cemiplimab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
The Effects of Plantar Flexion Training in People With Chronic Stroke
NCT03548090
Conditions: Stroke; Hemiplegic Gait
Interventions: Other: Skateboard exercise at an incline angle of 0 degrees and 50% body weight; Other: Skateboard exercise at an incline angle of 5 degrees and 50% body weight; Other: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight; Other: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight; Other: Control 4-week exercise intervention; Other: Experimental 4-week exercise intervention; Other: Over-ground multi-directional gait training; Other: Home exercise
Sponsors: The University of Texas Health Science Center, Houston; Texas Woman's University
Recruiting
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
NCT03546972
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Ductal Breast Carcinoma In Situ; Obesity; Overweight; Premalignant Lesion
Interventions: Other: Behavioral, Psychological or Informational Intervention; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
NCT03525873
Conditions: Advanced Malignant Neoplasm; Metastatic Malignant Neoplasm; Recurrent Malignant Neoplasm
Interventions: Other: Laboratory Biomarker Analysis; Drug: Methylphenidate; Other: Physical Activity; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)
NCT03525366
Condition: Gastric Antral Vascular Ectasia
Intervention: Other: Radiofrequency ablation
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03524170
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study
NCT03523767
Condition: Major Depressive Disorder
Interventions: Biological: S.typhi Injection; Biological: Normal Saline Injection
Sponsor: The University of Texas Health Science Center, Houston
Recruiting
Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy
NCT03523689
Conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs; Lung Neoplasm
Interventions: Procedure: Bronchoscopy; Procedure: Radial Probe Endobronchial Ultrasound
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Smartphone Mobile Applications in Enhancing Smoking Cessation Treatment in Current Smokers
NCT03519451
Condition: Current Every Day Smoker
Interventions: Other: Internet-Based Intervention; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
NCT03508570
Conditions: Malignant Peritoneal Neoplasm; Malignant Retroperitoneal Neoplasm; Peritoneal Carcinomatosis; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Cervical Carcinoma; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IV Cervical Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Pharmacokinetic Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction
NCT03502512
Condition: Mammoplasty Patient
Interventions: Other: Questionnaire Administration; Procedure: Reconstructive Surgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Glutathione in Mild Cognitive Impairment
NCT03493178
Condition: Mild Cognitive Impairment
Intervention: Dietary Supplement: N- acetylcysteine plus Glycine v Placebo (alanine)
Sponsors: Baylor College of Medicine; Nantz National Alzhimer's Center, Houston Methodist Hospital, Houston, TX
Recruiting
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer
NCT03491176
Conditions: Cutaneous Squamous Cell Carcinoma of the Head and Neck; Healthy Subject; Head and Neck Cancer
Interventions: Procedure: Biospecimen Collection; Procedure: Magnetic Resonance Imaging; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
NCT03485950
Condition: Other Infectious Diseases
Interventions: Drug: Cefepime; Drug: Ceftolozane; Other: Laboratory Biomarker Analysis; Drug: Meropenem; Drug: Piperacillin-Tazobactam; Drug: Tazobactam
Sponsors: M.D. Anderson Cancer Center; Merck Sharp & Dohme Corp.; National Cancer Institute (NCI)
Recruiting
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
NCT03473730
Conditions: Bladder Urothelial Carcinoma; Clear Cell Renal Cell Carcinoma; Malignant Urinary System Neoplasm; Metastatic Kidney Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Interventions: Procedure: Biopsy; Biological: Daratumumab; Other: Laboratory Biomarker Analysis; Procedure: Metastasectomy; Procedure: Nephrectomy
Sponsors: M.D. Anderson Cancer Center; Janssen Research & Development, LLC; National Cancer Institute (NCI)
Recruiting
MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
NCT03469284
Conditions: Malignant Neoplasm; Oral Pain; Stomatitis
Interventions: Other: Best Practice; Drug: Methylene Blue
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
NCT03465774
Condition: Malignant Pleural Effusion
Interventions: Drug: Doxycycline; Device: Indwelling Catheter; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Survey Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
NCT03460769
Conditions: Pancreatic Cancer; Chronic Pancreatitis; Diabetes Mellitus Type 3c
Intervention: Other: Data Management and Monitoring
Sponsors: M.D. Anderson Cancer Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
NCT03458676
Condition: Brain Lesion
Interventions: Procedure: Advanced Magnetic Resonance Imaging Scan; Procedure: Standard of Care Brain Biopsy and Tumor Removal
Sponsor: M.D. Anderson Cancer Center
Recruiting
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
NCT03452930
Conditions: Glioblastoma; Gliosarcoma; MGMT-Unmethylated Glioblastoma; Unmethylated MGMT Gene Promoter
Interventions: Radiation: Radiation Therapy; Drug: Tinostamustine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma
NCT03450122
Conditions: Malignant Neoplasms of Bone and Articular Cartilage; Malignant Neoplasms of Mesothelial and Soft Tissue; Synovial Sarcoma; Myxoid Liposarcoma; HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present; Recurrent Myxoid Liposarcoma; Recurrent Synovial Sarcoma
Interventions: Biological: Aldesleukin; Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes; Drug: Cyclophosphamide; Biological: Dendritic Cell-targeting Lentiviral Vector ID-LV305; Drug: Immunotherapeutic Combination Product CMB305
Sponsors: M.D. Anderson Cancer Center; Immune Design; National Cancer Institute (NCI)
Recruiting
Comprehensive Lifestyle Change To Prevent Breast Cancer
NCT03448003
Condition: Premenopausal
Interventions: Other: Cancer Prevention; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
TCR-engineered T Cells in Solid Tumors Including NSCLC and HCC Patients
NCT03441100
Conditions: Solid Tumor, Adult; Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Nonsmall Cell Lung Cancer; Liver Cancer; Lung Cancer
Interventions: Drug: IMA202 Product; Device: IMA_Detect
Sponsors: Immatics US, Inc.; M.D. Anderson Cancer Center
Recruiting
Inotuzumab Ozogamicin in Treating Participants With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
NCT03441061
Conditions: Acute Lymphoblastic Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation Recipient; B Acute Lymphoblastic Leukemia; Minimal Residual Disease; Philadelphia Chromosome Positive; Recurrent B Acute Lymphoblastic Leukemia
Intervention: Biological: Inotuzumab Ozogamicin
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
NCT03439085
Conditions: Human Papillomavirus-16 Positive; Human Papillomavirus-18 Positive; Metastatic Malignant Neoplasm; Recurrent Anal Canal Carcinoma; Recurrent Cervical Carcinoma; Recurrent Malignant Neoplasm; Recurrent Penile Carcinoma; Recurrent Vaginal Carcinoma; Recurrent Vulvar Carcinoma; Refractory Malignant Neoplasm; Stage IV Anal Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Vaginal Cancer AJCC v8; Stage IV Vulvar Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Vaginal Cancer AJCC v8; Stage IVA Vulvar Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Vaginal Cancer AJCC v8; Stage IVB Vulvar Cancer AJCC v8
Interventions: Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457; Biological: Durvalumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
NCT03436563
Conditions: Colon Adenocarcinoma; High-Frequency Microsatellite Instability; Metastatic Malignant Solid Neoplasm; Rectal Adenocarcinoma; Refractory Colorectal Carcinoma; Stage IV Colon Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8
Intervention: Biological: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT03435952
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract
Interventions: Drug: Pembrolizumab; Biological: Clostridium Novyi-NT; Drug: Doxycycline
Sponsors: M.D. Anderson Cancer Center; BioMed Valley Discoveries, Inc; Merck Sharp & Dohme Corp.
Recruiting
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
NCT03430882
Conditions: Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Sapanisertib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
NCT03429907
Condition: Malignant Neoplasm of Breast
Interventions: Behavioral: Mind-Body Exercises; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; Hackett Foundation
Recruiting
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Participants With Primary or Secondary Myelofibrosis
NCT03426969
Conditions: Hematopoietic Cell Transplantation Recipient; Primary Myelofibrosis; Secondary Myelofibrosis
Interventions: Drug: Cyclophosphamide; Biological: Filgrastim; Drug: Fludarabine Phosphate; Procedure: Hematopoietic Cell Transplantation; Drug: Melphalan; Drug: Mycophenolate Mofetil; Drug: Tacrolimus; Radiation: Total-Body Irradiation
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
NCT03422302
Conditions: Lung Carcinoma; Malignant Respiratory Tract Neoplasm; Metastatic Malignant Neoplasm in the Lung
Interventions: Device: Biphasic Positive Airway Pressure; Procedure: Computed Tomography; Procedure: Continuous Positive Airway Pressure; Procedure: Deep Inspiration Breath Hold; Radiation: Radiation Therapy Treatment Planning and Simulation; Radiation: Stereotactic Body Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Apalutamide in Treating Participants With Prostate Cancer Before Radical Prostatectomy
NCT03412396
Conditions: Prostate Adenocarcinoma; PSA Level Ten to Twenty; Stage IIB Prostate Cancer AJCC v8; Testosterone Greater Than 200 ng/dL
Interventions: Drug: Apalutamide; Other: Quality-of-Life Assessment; Procedure: Radical Prostatectomy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Early Detection of Breast Cancer in a Mammography Screening
NCT03408353
Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Other: Health Measurements
Sponsor: M.D. Anderson Cancer Center
Recruiting
Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
NCT03407001
Condition: Cirrhosis
Interventions: Procedure: Contrast-Enhanced Ultrasound; Drug: Sulfur Hexafluoride Lipid Microspheres; Procedure: Ultrasound
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Venetoclax in Combination With Decitabine in r/r AML
NCT03404193
Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10-20 Percent of Bone Marrow Nucleated Cells; Chronic Myelomonocytic Leukemia; High Risk Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent High Risk Myelodysplastic Syndrome; Recurrent Mixed Phenotype Acute Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory High Risk Myelodysplastic Syndrome; Refractory Mixed Phenotype Acute Leukemia; TP53 Gene Deletion; TP53 Gene Mutation
Interventions: Drug: Decitabine; Other: Laboratory Biomarker Analysis; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
NCT03398161
Conditions: Localized Skin Lesion; Mycosis Fungoides
Interventions: Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03390296
Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Biological: Anti-OX40 Agonist Monoclonal Antibody PF-04518600; Drug: Avelumab; Drug: Azacitidine; Drug: Gemtuzumab Ozogamicin; Drug: Glasdegib; Drug: Glasdegib Maleate; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
NCT03370718
Conditions: Metastatic Carcinoma in the Adrenal Cortex; Stage III Adrenal Cortex Carcinoma AJCC v8; Stage IV Adrenal Cortex Carcinoma AJCC v8; Unresectable Adrenal Cortex Carcinoma
Interventions: Drug: Cabozantinib; Other: Pharmacogenomic Study; Other: Pharmacokinetic Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients
NCT03360721
Conditions: Castration-resistant Prostate Cancer; Metastatic Castration Resistant Prostate Cancer
Interventions: Drug: Abiraterone Acetate 250 MG Oral Tablet [Zytiga]; Drug: Apalutamide; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; Janssen Scientific Affairs, LLC
Recruiting
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT03359954
Conditions: Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Positive
Interventions: Radiation: Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
NCT03359811
Condition: Peritoneal Cancer
Interventions: Drug: Local Anesthetic Solution; Drug: Bupivacaine HCl; Drug: Liposomal Bupivacaine
Sponsor: M.D. Anderson Cancer Center
Recruiting
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
NCT03323658
Conditions: Atypical Ductal Breast Hyperplasia; Atypical Lobular Breast Hyperplasia; BRCA1 Gene Mutation; BRCA2 Gene Mutation; Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Lobular Breast Carcinoma In Situ; No Evidence of Disease
Interventions: Drug: Bexarotene; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
NCT03319745
Conditions: Stage I Bladder Cancer AJCC v8; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8; Stage IIIB Bladder Cancer AJCC v8
Intervention: Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
NCT03318900
Conditions: COL6A3 Positive; HLA-A*0201 Positive Cells Present; PRAME Positive; Recurrent Ovarian Carcinoma
Interventions: Biological: Aldesleukin; Drug: CD8-Positive T-Lymphocyte; Drug: Cyclophosphamide; Procedure: Leukapheresis; Biological: Utomilumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
NCT03307616
Conditions: Dedifferentiated Liposarcoma; Recurrent Dedifferentiated Liposarcoma; Recurrent Undifferentiated Pleomorphic Sarcoma; Resectable Dedifferentiated Liposarcoma; Resectable Undifferentiated Pleomorphic Sarcoma; Undifferentiated Pleomorphic Sarcoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
NCT03300544
Conditions: Rectal Adenocarcinoma; Stage III Rectal Cancer AJCC v7; Stage IIIA Rectal Cancer AJCC v7; Stage IIIB Rectal Cancer AJCC v7; Stage IIIC Rectal Cancer AJCC v7; Stage IV Rectal Cancer AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Radiation: Radiation Therapy; Biological: Talimogene Laherparepvec
Sponsor: National Cancer Institute (NCI)
Recruiting
IACS-010759 in Treating Patients With Relapsed or Refractory Lymphoma or Solid Tumors That Are Advanced, Metastatic, or Unresectable
NCT03291938
Conditions: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Malignant Solid Neoplasm; Pancreatic Ductal Adenocarcinoma; Progesterone Receptor Negative; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Lymphoma; Refractory Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; Stage IIB Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm
Interventions: Drug: Oxidative Phosphorylation Inhibitor IACS-010759; Other: Pharmacodynamic Study; Other: Pharmacokinetic Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
RCT of QPS vs General Information Sheet
NCT03287492
Conditions: Advanced Malignant Neoplasm; Caregiver; Physician
Interventions: Other: Informational Intervention; Other: Questionnaire Administration
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
NCT03283917
Conditions: Newly Diagnosed Primary Amyloidosis; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Daratumumab; Drug: Dexamethasone; Drug: Ixazomib
Sponsors: M.D. Anderson Cancer Center; Janssen Pharmaceuticals; Takeda Pharmaceutical
Recruiting
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT03278782
Conditions: Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Pembrolizumab; Drug: Romidepsin
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
NCT03274258
Conditions: Kidney Medullary Carcinoma; Loss of INI 1 Protein Expression; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
NCT03265717
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Biological: INVAC-1
Sponsors: Invectys; M.D. Anderson Cancer Center
Recruiting
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
NCT03263572
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia; t(9;22)
Interventions: Biological: Blinatumomab; Drug: Cytarabine; Drug: Methotrexate; Drug: Ponatinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Amgen; Takeda
Recruiting
TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine)
NCT03247309
Conditions: Solid Tumor; Cancer; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer
Interventions: Biological: IMA201 Product; Diagnostic Test: IMA_Detect; Diagnostic Test: ACT-HLA
Sponsors: Immatics US, Inc.; M.D. Anderson Cancer Center
Recruiting
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
NCT03247088
Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient; Donor; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Busulfan; Drug: Cyclophosphamide; Biological: Filgrastim; Drug: Fludarabine; Drug: Mycophenolate Mofetil; Drug: Sorafenib; Drug: Tacrolimus
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
NCT03224000
Conditions: Malignant Neoplasms of Lip Oral Cavity and Pharynx; Oropharyngeal Cancer
Interventions: Procedure: Modified Barium Swallow (MBS); Behavioral: Swallowing Questionnaire; Behavioral: Symptom Questionnaire; Procedure: Video-Strobe Procedure; Procedure: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning; Procedure: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning; Radiation: Intensity Modulated Radiotherapy (IMRT)
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
NCT03222076
Conditions: Hepatocellular Carcinoma; Resectable Hepatocellular Carcinoma
Interventions: Biological: Ipilimumab; Biological: Nivolumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
NCT03219047
Conditions: Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
Interventions: Other: Best Practice; Drug: Ibrutinib; Other: Patient Derived Xenograft; Other: Personalized Medicine
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
NCT03217747
Conditions: Advanced Malignant Solid Neoplasm; Castration-Resistant Prostate Carcinoma; Malignant Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Prostate Carcinoma; Prostate Carcinoma Metastatic in the Bone; Refractory Malignant Solid Neoplasm; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Interventions: Biological: Anti-OX40 Antibody PF-04518600; Drug: Avelumab; Radiation: Radiation Therapy; Biological: Utomilumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
NCT03214562
Conditions: High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Biological: Filgrastim; Drug: Fludarabine; Drug: Fludarabine Phosphate; Drug: Idarubicin; Drug: Idarubicin Hydrochloride; Biological: Pegfilgrastim; Drug: Venetoclax
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
NCT03214510
Condition: Liver and Intrahepatic Bile Duct Disorder
Interventions: Drug: Bupivacaine; Drug: Fentanyl; Drug: Hydromorphone Hydrochloride; Device: Implanted Medical Device; Drug: Liposomal Bupivacaine; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03210662
Conditions: Recurrent Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pembrolizumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
NCT03207555
Conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
Sponsors: M.D. Anderson Cancer Center; Pharmacyclics LLC.
Recruiting
Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
NCT03207529
Condition: Malignant Neoplasm of Breast
Interventions: Drug: Alpelisib; Drug: Enzalutamide
Sponsors: M.D. Anderson Cancer Center; Novartis; Astellas Pharma Global Development, Inc.
Recruiting
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT03202316
Conditions: Edema; Erythema; Peau d'Orange; Recurrent Inflammatory Breast Carcinoma; Stage IV Inflammatory Breast Carcinoma
Interventions: Drug: Atezolizumab; Drug: Cobimetinib; Drug: Eribulin; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Your Health Matters! (Tu Salud ¡Si Cuenta!): Promoting Healthy Lifestyles in Latino Families
NCT03199209
Conditions: Family Member; Health Status Unknown
Interventions: Other: Behavioral, Psychological or Informational Intervention; Behavioral: Patient Visit; Other: Questionnaire Administration; Other: Text Message
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer
NCT03187951
Conditions: Other Disorders of Glucose Regulation and Pancreatic Internal Secretion; Pancreatic Cancer
Interventions: Behavioral: Questionnaires; Behavioral: Nutritional Questionnaire and Nutritional Counseling; Other: Booklet; Behavioral: Aerobic Exercise and Strength Training Exercises; Behavioral: Phone Calls; Behavioral: Physical Assessments
Sponsor: M.D. Anderson Cancer Center
Recruiting
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
NCT03181100
Conditions: Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Carcinoma
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Cobimetinib; Drug: Nab-paclitaxel; Drug: Paclitaxel; Drug: Vemurafenib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
NCT03177460
Conditions: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Testosterone Greater Than 150 ng/dL
Interventions: Biological: Daratumumab; Drug: FMS Inhibitor JNJ-40346527; Procedure: Radical Prostatectomy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now